LEARN. PREVENT. SCREEN. CERVICAL CANCER CAN BECOME HISTORY.

January is Cervical Cancer Awareness Month, and these three core principles are emphasized during the 2024 campaign. Nowadays, cervical cancer is responsible for more than 300,000 deaths each year globally. Fortunately, we have the tools to prevent it, diagnose it early, and treat it efficiently in most cases. This is why we need to become aware, stay alert, and take the necessary measures, as individuals and nations. MVision AI supports Radiation Oncology professionals in delivering efficient treatments for patients fighting cervical cancer.

Why is it important to be aware of cervical cancer?

  • Because it is diagnosed in more than 600,000 women and is the cause of losing more than 300,000 lives each year globally (1).
  • Because it is preventable. Persistent HPV infection is present in 99.7% of cervical cancer cases (2), and HPV vaccination decreases the incidence of new cases (3,4). Fortunately, 140 countries have already implemented HPV vaccination in their national immunization programs. Norway reported that there was no case of HPV-related cervical cancer among the first cohort of women who were offered vaccination as children (5).
  • Because when diagnosed in the early stages, the survival rate at 5 years is 80-90%, while for metastatic cases, it is only about 15% (6). Screening increases the chance of early detection and, therefore, of curing the patients (7).

Why is radiation therapy relevant for cervical cancer?

  • For the majority of patients diagnosed in localized stages, the combination of radiation therapy and chemotherapy is the primary treatment option.
  • In cases with metastatic disease, radiation therapy still plays an important role for selected patients (8).

How does MVision AI support cervical cancer patients?

If cervical cancer is diagnosed, patients need to start a personalized treatment – ideally, as soon as possible. When MVision AI Contour+ female pelvis mode is used as a starting point, the radiation therapy teams can provide a highly adapted treatment plan which is created faster compared with manual delineation (9-10). This comprehensive model offers a total of 49 structures, including 41 organs at risk and anatomical landmarks, 3 CTVs and 5 lymph nodes regions. We believe that for offering a quality treatment, guideline-based auto-contouring developed using AI is the new “must have” that increases productivity and consistency.

References

  1. Cervical cancer awareness month. https://www.tn.gov/content/dam/tn/health/program-areas/Cervical-Cancer-Awareness-Month-Toolkit-2024.pdf
  2. Okunade KS. Human papillomavirus and cervical cancer [published correction appears in J Obstet Gynaecol. 2020 May;40(4):590]. J Obstet Gynaecol. 2020;40(5):602-608. doi:10.1080/01443615.2019.1634030
  3. Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst. 2021;113(10):1329-1335. doi:10.1093/jnci/djab080
  4. Ren X, Hao Y, Wu B, et al. Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: A meta-analysis. Front Microbiol. 2022;13:1052324. Published 2022 Dec 2. doi:10.3389/fmicb.2022.1052324
  5. Global partners cheer progress towards eliminating cervical cancer and underline challenges. https://www.who.int/news/item/17-11-2023-global-partners-cheer-progress-towards-eliminating-cervical-cancer-and-underline-challenges
  6. Canadian Cancer Society – Cervical cancer facts. https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival/survival-statistics
  7. Landy R, Sasieni PD, Mathews C, et al. Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Int J Cancer. 2020;147(3):887-896. doi:10.1002/ijc.32826
  8. NCCN gGuidelines Cervical cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical_blocks.pdf
  9. B. Bordigoni, et al MO-03.9 – COMPREHENSIVE COMPARISON OF FOUR AUTOMATIC TOOLS IN OAR SEGMENTATION FOR GYNAECOLOGICAL RADIOTHERAPY, Physica Medica, Volume 115, Supplement 1, 2023, 102806, ISSN 1120-1797,https://doi.org/10.1016/j.ejmp.2023.102806.
  10. https://it-posters.com/seor2022/poster/view?id=895

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

26.8.2024

Lung Cancer Awareness–Examining Tobacco’s Effect

As August comes to a close, we take a moment to reflect on World Lung Cancer Day, observed earlier this month. This year’s focus has underscored the critical fact that tobacco smoking remains the leading cause of lung cancer. Understanding this connection is essential for both prevention and treatment, emphasizing…

News

6.8.2024

MVision AI Secures CDSCO Approval to Revolutionize Cancer Treatment Planning in India

HELSINKI, Finland – August, 2024 MVision AI is excited to announce that our application for MVision AI Segmentation (Contour+) has been approved by the Central Drugs Standard Control Organization (CDSCO) under the “Image Segmentation Application Software” category. This approval facilitates the deployment of our advanced image analysis algorithms in radiation…

Press Releases

2.7.2024

Breaking New Ground: MVision AI Contour+ for Upright MRI Scans

Results on testing MVision AI Contour+ for an ingenious and modern approach in radiation therapy have been recently presented at the 62nd Particle Therapy Co-Operative Group (PTCOG) conference in Singapore. Despite being trained using supine MR data and a different magnetic strength from different scanners, authors reported that MVision AI's…

Articles